ReviewImmunologic research2025
Serum amyloid A: multifaceted roles in inflammation and cellular interactions.
Review in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma extracellular vesicle proteomic analysis identifies WARS as a potential biomarker of infectious mononucleosis.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum amyloid A (SAA) is a conserved family of acute-phase proteins primarily produced in the liver but also expressed in extrahepatic tissues during inflammation. As a key component of the acute-phase response, SAA exhibits dynamic upregulation, with serum levels rising up to 1000-fold during inflammation, underscoring its significance in immune modulation and disease pathogenesis. This review provides a comprehensive analysis of SAA's structure, origins, and functions, emphasizing its interactions with immune and non-immune cells. SAA influences cellular processes such as cytokine production, leukocyte migration, and receptor activation, linking it to the pathogenesis of inflammation related diseases. Notably, SAA facilitates chronic inflammation, fibrosis, and therapy resistance while also playing protective roles in infection and tissue repair. The review highlights emerging insights into SAA's dual roles as both a biomarker and a therapeutic target. It underscores critical gaps in understanding SAA's context-dependent effects, receptor interactions, and its regulatory mechanisms in diverse inflammatory settings. These findings point to the necessity of further research to harness SAA's diagnostic and therapeutic potential, particularly in chronic inflammatory and autoimmune diseases. By synthesizing current evidence, this work aims to guide future studies toward advancing clinical interventions targeting SAA-mediated pathways.
Indexed as
Identifiers
41114879What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.